Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Brimonidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 20/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 19/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 19/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 14/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 11/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 12/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | HTR1A | P08908 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | HPGD | P15428 | 1/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brimonidine SCHEMBL27455839 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL29377437 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL29356891 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL29470063 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL2400529 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL29378438 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL34649 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL22616168 | 0.99 | ADRA2A (0.98) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL22616169 | 0.99 | ADRA2A (0.98) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL29227701 | 0.99 | ADRA2A (0.98) | ADRA2AADRA2BADRA2CADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5623 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736853-A2 | DEGRADANT COMPOUND IN A MEDICAMENT | Visus Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4724839-A2 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS | Mediprint Ophthalmics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260090984-A1 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS | MEDIPRINT OPHTHALMICS INC. (US) | 2026-04-02 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4236932-B1 | DEGRADANT COMPOUND IN A MEDICAMENT | VISUS THERAPEUTICS INC (US) | 2026-01-07 | — | — | EP | claimed |
| US-20260000634-A1 | CARBACHOL FORMULATIONS TO ENHANCE ANTI-PRESBYOPIA EFFECTS | HERCULES CAPITAL, INC., AS AGENT | 2026-01-01 | — | — | US | claimed |
| US-20250387325-A1 | FIXED DOSE COMBINATION OF BRIMONIDINE AND TIMOLOL | ALLERGAN INC (US) | 2025-12-25 | — | — | US | claimed |
| EP-4662203-A1 | BINDARIT CONJUGATES, COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES OR DISORDERS | Translatum Medicus Inc. (CA) | 2025-12-17 | — | — | EP | claimed |
| US-20250339378-A1 | THERMORESPONSIVE HYDROGEL CONTAINING POLYMER MICROPARTICLES FOR NONINVASIVE OCULAR DRUG DELIVERY | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2025-11-06 | — | — | US | claimed |
| EP-3946183-B1 | A FLOW CONTROL DEVICE FOR DELIVERING AN OPHTHALMIC FORMULATION | TEARCLEAR CORP (US) | 2025-10-29 | — | — | EP | claimed |
| US-20040219219-A1 | Compositions containing alpha-2-adrenergic agonist components | ALLERGAN, INC. | 2004-11-04 | — | — | US | claimed |
| US-20040214829-A1 | Compositions containing alpha-2-adrenergic agonist components | ALLERGAN, INC. | 2004-10-28 | — | — | US | claimed |
| CN-1133466-C | Gelling ophthalmic compositions containing xanthan gum | ������ʵ���ҹ�˾ | 2004-01-07 | — | — | CN | claimed |
| US-20030181354-A1 | Method for central nervous system targeting through the ocular route of drug delivery | ABDULRAZIK MUHAMMAD (IL) | 2003-09-25 | — | — | US | claimed |
| CN-1368878-A | Drug therapy of restless leg syndrome | BOEHRINGER INGELHEIM PHARMA (DE) | 2002-09-11 | — | — | CN | claimed |
| US-6410045-B1 | POLYMERIC HYDROGEL CONTAINING TIMOLOL MALEATE | EAGLE RAY INC | 2002-06-25 | — | — | US | claimed |
| US-20010049369-A1 | Brimonidine compositions and methods for retinal degeneration | UNIVERSITY OF TENNESSEE RESEARCH CORPORATION, THE | 2001-12-06 | — | — | US | claimed |
| CN-1295483-A | Gelling ophthalmic composition containing xanthan gum | ALCON LAB INC (US) | 2001-05-16 | — | — | CN | claimed |
| EP-0719139-A1 | USE OF CENTRALLY ACTIVE ALPHAAGONISTS FOR INHIBING POSTRAUMATIC METABOLIC STRESS | Dr. Karl Thomae GmbH (DE) | 1996-07-03 | — | — | EP | claimed |
| WO-1995003798-A2 | USE OF CENTRALLY EFFECTIVE α-2 AGONISTS FOR INHIBITING POSTAGGRESSION METABOLISM | BOEHRINGER INGELHEIM INT (DE) | 1995-02-09 | — | — | WO | claimed |